Moderna Raises 2026 Revenue Growth Outlook to 15%–25%
Moderna now expects 2026 revenue growth of 15% to 25%, up from previous guidance of up to 10%, citing stronger international demand for its Covid-19 vaccines. Third-quarter revenue rose 29% to $1.31 billion from $1.02 billion a year earlier.
The company now expects revenue growth of 15% to 25% in 2026, up from previous guidance of up to 10%, driven by stronger demand for its Covid-19 vaccines in international markets.Third-quarter revenue jumped 29% to $1.31bn from $1.02bn a year earlier, with US sales contributing $780m and internatio…